Effectiveness of a Cardiovascular Risk Intervention Program in Patients With Schizophrenia (PRISCA)
NCT ID: NCT04276012
Last Updated: 2020-09-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
130 participants
INTERVENTIONAL
2020-01-20
2021-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Main measurements: the global CVR at baseline and at six-month follow-up through Framingham tables calibrated for the Catalan population (Registre Gironí del Cor, REGICOR). Secondary measures: they will be determined, at baseline and at six-month follow-up, four cardiovascular risk factors as well: hypertension, hypercholesterolemia, hyperglycaemia and smoking, according with the latest recommendations of the Program of preventive activities and health promotion (PAPPS) of the Spanish Society of Family and Community Medicine. Other measures: anthropometric parameters. Functional Assessment Screening Tool (FAST) and quality of life (EQ-5D).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Promoting Physical Activity in People With Schizophrenia.
NCT03514212
Risk Prediction Model of Cardiovascular Events in Patients With Schizophrenia
NCT05498571
Effectiveness of a Lifestyle Intervention for Increasing Physical Activity in Adults With Schizophrenia
NCT00338832
PROFILe3: Epidemiologic Survey in Patients With Schizophrenia or Schizoaffective Disorders
NCT00399334
Evaluation of the Functional Remission Occurrence and Predictive Factors in Schizophrenia
NCT02874560
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention group
The intervention group will participate in different intervention strategy depending on the individual needs (psychoeducational, recommendations of life style and diet, medication adherence and changes in pharmacological strategy)
Multifactorial intervention
Psychoeducational intervention, recommendations on life style and diet, medication adherence and changes in pharmacological strategy
Control group
Usual clinical care
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Multifactorial intervention
Psychoeducational intervention, recommendations on life style and diet, medication adherence and changes in pharmacological strategy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dr. Pere Roura-Poch
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Pere Roura-Poch
Epidemiologist
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vic Hospital Consortium
Vic, Catalonia, Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Riera-Molist N, Assens-Tauste M, Roura-Poch P, Guimera-Gallent M, Santos-Lopez JM, Serra-Millas M, Frau-Rossello N, Gallego-Pena E, Foguet-Boreu Q. A Cardiovascular Risk Optimization Program in People With Schizophrenia: A Pilot Randomized Controlled Clinical Trial. J Psychiatr Pract. 2023 Nov 1;29(6):456-468. doi: 10.1097/PRA.0000000000000743.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AC-274
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.